The FDA approved Novo Nordisk’s semaglutide tablet Rybelsus for adults with diabetes but not for weight management. Mild gastrointestinal issues, such as nausea and diarrhea, were the most ...
Zacks.com on MSN8d
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price CutsNovo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback